X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (63113) 63113
Publication (6412) 6412
Newspaper Article (1506) 1506
Book Review (606) 606
Newsletter (482) 482
Book Chapter (296) 296
Magazine Article (148) 148
Conference Proceeding (103) 103
Trade Publication Article (96) 96
Transcript (92) 92
Dissertation (49) 49
Book / eBook (28) 28
Data Set (20) 20
Report (14) 14
Streaming Video (13) 13
Reference (5) 5
Presentation (4) 4
Web Resource (4) 4
Paper (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (47124) 47124
index medicus (33674) 33674
male (27108) 27108
female (24057) 24057
middle aged (17824) 17824
animals (16969) 16969
adult (16533) 16533
antigens (15313) 15313
immunology (13901) 13901
aged (12085) 12085
oncology (10211) 10211
cancer (8821) 8821
mice (8221) 8221
immunotherapy (7200) 7200
treatment outcome (6929) 6929
research (6237) 6237
health aspects (6166) 6166
lymphocytes (5930) 5930
transplantation (5898) 5898
analysis (5892) 5892
care and treatment (5797) 5797
hematology (5723) 5723
adolescent (5666) 5666
risk factors (5208) 5208
patients (5094) 5094
proteins (5075) 5075
vaccines (4805) 4805
expression (4706) 4706
medicine (4630) 4630
medicine, research & experimental (4469) 4469
therapy (4421) 4421
t cells (4308) 4308
prostate cancer (4263) 4263
surgery (4156) 4156
chemotherapy (4110) 4110
tumors (4108) 4108
lymphocytes t (4049) 4049
antibodies (4046) 4046
research article (4017) 4017
clinical trials (4004) 4004
inflammation (3947) 3947
child (3898) 3898
cytokines (3852) 3852
aged, 80 and over (3851) 3851
time factors (3847) 3847
antigen (3754) 3754
prognosis (3729) 3729
disease (3708) 3708
article (3607) 3607
medical research (3566) 3566
immune system (3556) 3556
infections (3548) 3548
studies (3539) 3539
dendritic cells (3501) 3501
young adult (3501) 3501
multidisciplinary sciences (3477) 3477
vaccination (3456) 3456
retrospective studies (3368) 3368
infectious diseases (3364) 3364
immune response (3211) 3211
gene expression (3139) 3139
prostate-specific antigen - blood (3026) 3026
science (3015) 3015
survival (3013) 3013
urology & nephrology (2971) 2971
apoptosis (2967) 2967
t-lymphocytes - immunology (2959) 2959
diagnosis (2832) 2832
cell biology (2768) 2768
immunization (2766) 2766
metastasis (2760) 2760
flow cytometry (2750) 2750
immunoglobulins (2728) 2728
follow-up studies (2681) 2681
allergy (2678) 2678
cancer therapies (2670) 2670
infection (2670) 2670
stem cells (2666) 2666
medicine & public health (2660) 2660
risk (2644) 2644
mortality (2632) 2632
drug therapy (2602) 2602
immunohistochemistry (2592) 2592
cd4 antigen (2585) 2585
pharmacology & pharmacy (2572) 2572
cells (2507) 2507
child, preschool (2445) 2445
disease models, animal (2440) 2440
prospective studies (2401) 2401
abridged index medicus (2391) 2391
t-cells (2331) 2331
children (2279) 2279
activation (2266) 2266
gastroenterology & hepatology (2234) 2234
rats (2223) 2223
antibodies, monoclonal - therapeutic use (2177) 2177
immunity (2171) 2171
genetic aspects (2126) 2126
pathology (2123) 2123
physiological aspects (2105) 2105
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (63627) 63627
German (489) 489
Japanese (401) 401
French (400) 400
Russian (341) 341
Chinese (243) 243
Spanish (149) 149
Polish (116) 116
Italian (65) 65
Czech (26) 26
Hungarian (22) 22
Swedish (21) 21
Danish (20) 20
Portuguese (16) 16
Dutch (14) 14
Korean (11) 11
Norwegian (11) 11
Bulgarian (9) 9
Croatian (9) 9
Hebrew (9) 9
Ukrainian (8) 8
Finnish (7) 7
Turkish (6) 6
Romanian (5) 5
Serbian (3) 3
Slovak (3) 3
Lithuanian (2) 2
Afrikaans (1) 1
Arabic (1) 1
Greek (1) 1
Icelandic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 07/2017, Volume 377, Issue 4, pp. 338 - 351
Journal Article
Critical Care, ISSN 1364-8535, 04/2017, Volume 21, Issue 1, pp. 89 - 89
Pharmacological and cellular treatment of cancer is changing dramatically with benefits for patient outcome and comfort, but also with new toxicity profiles.... 
Interdisciplinary management | Targeted therapy | Toxicity | Immunotherapy | Cancer | SAFETY | RISK | CHRONIC MYELOID-LEUKEMIA | TYROSINE KINASE INHIBITORS | THERAPY | BLINATUMOMAB | ARTERIAL OCCLUSIVE DISEASE | RECEPTOR T-CELLS | ADVERSE EVENTS | IPILIMUMAB | CRITICAL CARE MEDICINE | Immunotherapy - methods | Pyrazoles - therapeutic use | Drug-Related Side Effects and Adverse Reactions - complications | Humans | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Intensive Care Units - organization & administration | Immunotherapy - adverse effects | Neoplasms - drug therapy | Antibodies, Bispecific - therapeutic use | Antibodies, Bispecific - adverse effects | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Systemic Inflammatory Response Syndrome - etiology | Systemic Inflammatory Response Syndrome - complications | Drug-Related Side Effects and Adverse Reactions - physiopathology | Systemic Inflammatory Response Syndrome - drug therapy | Drug-Related Side Effects and Adverse Reactions - diagnosis | Cytokines - adverse effects | Pyrazoles - adverse effects | Cardiac arrhythmia | Disease | Leukemia | Colorectal cancer | Cytotoxicity | Kinases | Cancer therapies | Proteins | Neurotoxicity | Cell growth | Ischemia | Pharmaceutical industry | Vascular endothelial growth factor | Antigens | Immunoglobulins | Cytokines | Diarrhea | Breast cancer | Patients | Meta-analysis | Inflammatory bowel disease | Chemotherapy | Lymphomas | Tumors | Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2015, Volume 54, pp. 139 - 148
Journal Article
Gastroenterology, ISSN 0016-5085, 2017, Volume 152, Issue 5, pp. 1078 - 1089
Background & Aims We performed a genome-wide association study (GWAS) to identify genetic risk factors for drug-induced liver injury (DILI) from licensed drugs... 
Gastroenterology and Hepatology | Side Effect | Medication | Liver Damage | Anti-Fungal Agent | POPULATION | SUSCEPTIBILITY | RISK | TERBINAFINE | TICLOPIDINE | HEPATITIS | CLASS-I | HEPATOTOXICITY | GASTROENTEROLOGY & HEPATOLOGY | T-CELLS | ANTIGEN | Antifungal Agents - adverse effects | Naphthalenes - adverse effects | Humans | Middle Aged | Male | Sertraline - adverse effects | Fenofibrate - adverse effects | Chromosomes, Human, Pair 2 - genetics | Ticlopidine - adverse effects | Female | Odds Ratio | Chemical and Drug Induced Liver Injury - etiology | Platelet Aggregation Inhibitors - adverse effects | Hypolipidemic Agents - adverse effects | European Continental Ancestry Group - genetics | Genetic Predisposition to Disease | Genome-Wide Association Study | Genes, MHC Class I - genetics | Chemical and Drug Induced Liver Injury - genetics | Terbinafine | Phenotype | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Alleles | HLA-A Antigens - genetics | Polymorphism, Single Nucleotide | Antidepressive Agents - adverse effects | Drugs | Medical research | Liver diseases | Liver | Genes | Genomics | Risk factors | Genetic polymorphisms | Analysis | Gastrointestinal diseases | Medicine, Experimental | Genetic research | Trade and professional associations | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Hépatology and Gastroenterology | side effect | medication | anti-fungal agent | liver damage | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Gastroenterologi | Klinisk medicin
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 7, pp. 597 - 605
Summary Background Rates of sustained virological response (SVR) to peginterferon–ribavirin are low in patients with hepatitis C virus (HCV) genotype 1 and... 
Infectious Disease | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Recombinant Proteins - adverse effects | Viral Load | Drug-Related Side Effects and Adverse Reactions - pathology | Young Adult | Drug Therapy, Combination - adverse effects | HIV-1 - isolation & purification | Placebos - adverse effects | Ribavirin - administration & dosage | Adult | Female | Placebos - administration & dosage | Proline - administration & dosage | Hepacivirus - isolation & purification | Double-Blind Method | Proline - analogs & derivatives | HIV Infections - virology | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | HIV Infections - complications | Aged | Hepacivirus - classification | Interferon-alpha - adverse effects | Medical colleges | Interferon alpha | Clinical trials | HIV (Viruses) | Biological response modifiers | Ribavirin | Viral antigens | Virus diseases | Genetic aspects | Product development | Drug therapy | Hepatitis C virus | HIV infection
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1019 - 1026
Summary Background Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide,... 
Hematology, Oncology and Palliative Medicine | THERAPY | OLDER PATIENTS | ONCOLOGY | FEBRILE NEUTROPENIA | PCI-32765 | CHRONIC LYMPHOCYTIC-LEUKEMIA | CLASSIFICATION | RANDOMIZED CONTROLLED-TRIAL | TARGETING BTK | ELDERLY-PATIENTS | CHEMOTHERAPY | Doxorubicin - therapeutic use | Pyrazoles - therapeutic use | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Dose-Response Relationship, Drug | Young Adult | Non-Randomized Controlled Trials as Topic | Aged, 80 and over | Adult | Female | Lymphoma, Non-Hodgkin - drug therapy | Pyrazoles - adverse effects | Severity of Illness Index | Antigens, CD20 - immunology | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Administration, Oral | Rituximab | Survival Rate | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Antigens, CD20 - drug effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Lymphoma, Non-Hodgkin - diagnosis | Care and treatment | Anthracyclines | Cyclophosphamide | Prednisone | Corticosteroids | Tumors
Journal Article
Archives of Dermatological Research, ISSN 0340-3696, 1/2009, Volume 301, Issue 1, pp. 99 - 105
Drug-induced lupus erythematosus (DILE) is defined as a lupus-like syndrome temporally related to continuous drug exposure which resolves after discontinuation... 
Drug-induced lupus erythematosus | Antinuclear antibodies (ANA) | Medicine & Public Health | Dermatology | Anti-TNFα-induced lupus | Anti-histone antibodies | Subacute cutaneous drug-induced lupus (SCLE) | Drug reactions | RHEUMATOID-ARTHRITIS | AUTOANTIBODIES | ANTINUCLEAR | NECROSIS-FACTOR-ALPHA | INDUCTION | DERMATOLOGY | Anti-TNF alpha-induced lupus | THERAPY | INFLIXIMAB | ASSOCIATION | EPIDEMIOLOGY | PSORIASIS | Antifungal Agents - adverse effects | Antitubercular Agents - adverse effects | Naphthalenes - adverse effects | Antibodies - metabolism | Calcium Channel Blockers - adverse effects | Serositis | Exanthema | Humans | Isoniazid - adverse effects | Interferons - adverse effects | Antihypertensive Agents - administration & dosage | Sodium Chloride Symporter Inhibitors - adverse effects | Arthritis | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Lupus Erythematosus, Systemic - immunology | Sodium Chloride Symporter Inhibitors - administration & dosage | Tumor Necrosis Factor-alpha - immunology | Antibodies - immunology | Lupus Erythematosus, Cutaneous - chemically induced | Procainamide - administration & dosage | Lupus Erythematosus, Cutaneous - immunology | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Anti-Arrhythmia Agents - administration & dosage | Procainamide - adverse effects | Antihypertensive Agents - adverse effects | Hydralazine - adverse effects | Isoniazid - administration & dosage | Lupus Erythematosus, Systemic - diagnosis | Interferons - administration & dosage | Hydralazine - administration & dosage | Animals | Anti-Arrhythmia Agents - adverse effects | Naphthalenes - administration & dosage | Calcium Channel Blockers - administration & dosage | Antitubercular Agents - administration & dosage | Lupus Erythematosus, Systemic - chemically induced | Antifungal Agents - administration & dosage | Lupus Erythematosus, Cutaneous - diagnosis | Lupus | Antigen-antibody reactions | Enzymes | Antigens | Biological products | Antibodies | Viral antibodies | Enzyme inhibitors | Systemic lupus erythematosus | Fluocinolone acetonide | Calcium channel blockers | Diuretics | Kidney diseases | Hydralazine | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 21, pp. 2691 - 2697
Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152)-ipilimumab and tremelimumab-have been... 
REGRESSION | METASTATIC MELANOMA | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | EFFICACY | ONCOLOGY | PHASE-II | MONOCLONAL-ANTIBODY | CTLA-4 | PATIENT | CANCER-IMMUNOTHERAPY | BLOCKADE | Stevens-Johnson Syndrome - immunology | Peripheral Nervous System Diseases - chemically induced | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Antibodies, Monoclonal - adverse effects | Scleritis - chemically induced | Antineoplastic Agents - administration & dosage | Liver - immunology | Liver - drug effects | Antineoplastic Agents - adverse effects | Diarrhea - immunology | Pancreatitis - immunology | Scleritis - immunology | Mucous Membrane - drug effects | Colitis - immunology | Peripheral Nervous System Diseases - immunology | Antibodies, Monoclonal - immunology | Drug Eruptions - immunology | Skin - immunology | Melanoma - metabolism | Skin Neoplasms - pathology | Skin Neoplasms - immunology | Antineoplastic Agents - immunology | CTLA-4 Antigen - drug effects | Lymphatic Diseases - immunology | Antibodies, Monoclonal - pharmacokinetics | CTLA-4 Antigen - immunology | Pancreatitis - chemically induced | Melanoma - secondary | Chemical and Drug Induced Liver Injury - immunology | Pituitary Gland - immunology | Skin Neoplasms - metabolism | Lymphatic Diseases - chemically induced | Mucous Membrane - immunology | Antibodies, Monoclonal - administration & dosage | Melanoma - immunology | Uveitis - immunology | Melanoma - drug therapy | Uveitis - chemically induced | Pituitary Gland - drug effects | Skin - drug effects | Index Medicus
Journal Article